Table 3 Medication.

From: Risk factors associated with cytomegalovirus reactivation in patients receiving immunosuppressive therapy for rheumatic diseases: a retrospective study

 

CMV-positive patients (n = 85)

CMV-negative patients (n = 387)

p value

Maximum dose of PSL, mean ± SD, mg/day

552.4 ± 621.1

243.3 ± 510.4

< 0.0001

Cumulative amounts of PSL, mean ± SD, mg

2785.9 ± 2018.8

1330.5 ± 1611.1

< 0.0001

Intravenous cyclophosphamide, n (%)

23 (27.1%)

44 (11.4%)

< 0.0001

Azathioprine, n (%)

20 (23.5%)

55 (14.2%)

0.0053

Tacrolimus, n (%)

19 (22.4%)

81 (20.9%)

0.0977

Methotrexate, n (%)

13 (15.3%)

112 (28.9%)

0.0014

Salazosulfapyridine, n (%)

8 (9.4%)

92 (23.8%)

0.0004

Rituximab, n (%)

8 (9.4%)

8 (2.1%)

< 0.0001

Cyclosporine, n (%)

7 (8.2%)

14 (3.6%)

0.0101

Mizoribine, n (%)

6 (7.1%)

34 (8.8%)

0.0858

Bucillamine, n (%)

3 (3.5%)

36 (9.3%)

0.0133

Iguratimod, n (%)

3 (3.5%)

14 (3.6%)

0.1036

Mycophenolate Mofetil, n (%)

1 (1.2%)

14 (3.6%)

0.0409

Sarilumab, n (%)

1 (1.2%)

6 (1.6%)

0.0989

Sodium aurothiomalate, n (%)

1 (1.2%)

5 (1.3%)

0.1032

Baricitinib, n (%)

1 (1.2%)

3 (0.8%)

0.0944

Back to article page